Revolutionizing Lung Cancer Detection: The Role of AI-Derived CAD Software

By HEOR Staff Writer

July 12, 2023

Artificial Intelligence (AI)-derived computer-aided detection (CAD) software may be a game-changer in the field of lung cancer screening. These technologies can potentially enhance the detection and measurement of lung nodules in CT scan images, making them a cost-effective solution. However, more evidence is needed to ascertain which technologies are the most clinically and cost-effective.

There is little clinical-effectiveness evidence available on any of the individual technologies which means that more research is needed to fully understand the potential benefits and drawbacks of these technologies. For example, the software could potentially identify more people with benign lung nodules, leading to unnecessary anxiety and CT surveillance. 

Despite these uncertainties, the potential benefits of AI-derived CAD software cannot be ignored. Not only can it potentially increase the detection of lung nodules, but it can also improve reporting of nodule characteristics, assess the growth of lung nodules, and reduce the time to review and report CT scans. 

NICE encourages centres using AI-derived CAD software as part of targeted lung cancer screening to continue generating evidence and sharing their findings. This will help to realise the full potential of these technologies and facilitate comparisons between different software.

Recommendations for further research on the effect of using the software on clinical decision making and the effect of using the software on scan review and reporting time, are listed in the guideline.

Reference url

Recent Posts

Strategic Avalere Health Appointments Enhance Leadership in Navigating US Healthcare Policy Changes

By João L. Carapinha

December 17, 2025

Avalere Health strengthened its appointments, with Matt Kazan returning as Senior Vice President of Policy, where he previously served as a former top advisor on the US Senate Committee on Finance, and he will now lead the policy team amid changes like the Inflation Reduction Act. Laura Housman, ...
Positive ARTISTRY-2 Trial Results for BIC LEN HIV Regimen
BIC/LEN HIV Regimen Delivers Non-Inferior Results in ARTISTRY-2 Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial, demonstrating that the investigational BIC LEN HIV regimen
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Patients

By HEOR Staff Writer

December 16, 2025

Accelerating Review for Transformative Multiple Myeloma Therapy The U.S. Food and Drug Administration (